Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study
Romain Courcelle, Stéphane Gaudry, Nicolas Serck, Gauthier Blonz, Jean-Baptiste Lascarrou, David Grimaldi, on behalf the COVADIS study group, Nadia Aïssaoui, Giuseppe Carbutti, Alain D’hondt, Julien Higny, Geoffrey Horlait, Sami Hraiech, Laurent Lefèbvre, François Lejeune, André Ly, Michaël Piagnerelli, Bertrand Sauneuf, Thibaud Soumagne, Piotr Szychowiak, Julien Textoris, Benoit Vandenbunder, Christophe Vinsonneau
Abstract
SCOPUS: le.j
Topics & Concepts
MedicineObservational studyNeuromuscular Blocking AgentsCoronavirus disease 2019 (COVID-19)Acute respiratory distressSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBlocking (statistics)Multicenter studyRespiratory distressIntensive care medicineAnesthesiaEmergency medicineInternal medicineVirologyRandomized controlled trialLungStatisticsDiseaseMathematicsOutbreakInfectious disease (medical specialty)Respiratory Support and MechanismsIntensive Care Unit Cognitive DisordersAnesthesia and Sedative Agents